Product Information

TOBRAMYCIN-DEXAMETH OPHTH SUSP is a generic product labeled by Padagis US LLC, priced at $3.6789 per ML under NDC 00574403105. Its NADAC has been published 234 times since Jun 1, 2022.

FDA first approved this application on Feb 11, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TOBRAMYCIN-DEXAMETH OPHTH SUSP

tobramycin and dexamethasone
$3.6789per ML

Strength

1; 3 mg/mL; mg/mL

Manufacturer

Padagis US LLC

NDC

00574403105

Classification

Generic

Dosage Form

SUSPENSION/ DROPS

Route

OPHTHALMIC

Effective Date

11/18/2026

Active Ingredients

DEXAMETHASONE; TOBRAMYCIN

Approval Type

Generic (ANDA)

FDA Application

ANDA212715

FDA Approved

2/11/2022

TE Code

AB

On Market Since

3/17/2022

Pharmacological Classes

Aminoglycoside Antibacterial
Aminoglycosides
Corticosteroid Hormone Receptor Agonists
Corticosteroid

Price Statistics

The NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has been published 234 times since Jun 1, 2022, and over the history we have for it it has declined 73.0%. The table below summarizes its recorded NADAC range and movement.

Current price$3.6789 per ML
All-time high$14.4896 (Jul 13, 2022)
All-time low$3.6789 (Nov 18, 2026)
52-week high$4.7783
52-week low$3.6789
Median price$4.4730
Average price$5.4691
Largest weekly change+49.3% (Nov 22, 2023)
Weeks tracked234
Tracking sinceJun 1, 2022

Price History

1W

-2.3%

1M

-2.3%

3M

-13.8%

6M

-19.4%

1Y

-14.5%

3Y

-31.9%

5Y

N/A

All

-73.0%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of TOBRAMYCIN-DEXAMETH OPHTH SUSP?

The current National Average Drug Acquisition Cost (NADAC) for TOBRAMYCIN-DEXAMETH OPHTH SUSP, manufactured by Padagis US LLC, is $3.6789 per ML (NDC 00574403105), effective Nov 18, 2026.

How has the price of TOBRAMYCIN-DEXAMETH OPHTH SUSP changed over time?

Over the history we have for it, the NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has declined 73.0%. It has been tracked across 234 weekly CMS publications since Jun 1, 2022.

What are the highest and lowest recorded NADAC prices for TOBRAMYCIN-DEXAMETH OPHTH SUSP?

Since Jun 1, 2022, the NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has ranged from a low of $3.6789 (Nov 18, 2026) to a high of $14.4896 (Jul 13, 2022), with a median of $4.4730 per ML.

Are there cheaper alternatives to TOBRAMYCIN-DEXAMETH OPHTH SUSP?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as TOBRAMYCIN-DEXAMETH OPHTH SUSP in a comparable dosage form, but none are currently priced below it.

Who manufactures TOBRAMYCIN-DEXAMETH OPHTH SUSP?

TOBRAMYCIN-DEXAMETH OPHTH SUSP (NDC 00574403105) is labeled by Padagis US LLC, and CMS classifies it as a generic product.